Jamjoom Pharma has partnered with Bioventure Healthcare (BVH), a subsidiary of Mubadala Bio, to expand patient access to Ustekinumab in the United Arab Emirates.

Under the agreement, Jamjoom Pharma will serve as the exclusive commercial arm for BVH’s Ustekinumab product in the UAE, leading product commercialization and engagement with healthcare professionals in compliance with applicable regulatory requirements.

The partnership combines BVH’s pharmaceutical portfolio and quality capabilities with Jamjoom Pharma’s established commercial presence, operational scale and expertise in healthcare professional engagement across the UAE and the Middle East and Africa (MEA) region.

The collaboration reflects both companies’ commitment to improving patient access to specialty care and supporting the UAE’s healthcare ecosystem.